Jorge A. Garcia, MD, FACP, chairperson of the Oncologic

Drugs Advisory Committee (ODAC) for the US Food & Drug Administration,

shared insight on the recent ODAC meeting where members determined that

olaparib plus abiraterone as an upfront treatment for mCRPC should be

restricted to patients with BRCA mutations. Dr. Garcia is a medical oncologist

at the University Hospitals Seidman Cancer Center and is the center’s George

& Edith Richman Distinguished Scientist Chair, as well as Chief of their

Solid Tumor Oncology division.